Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37


Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.

Saunders EJ, Dadaev T, Leongamornlert DA, Al Olama AA, Benlloch S, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pasayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Teixeira MR, Pandha H, Govindasami K, Muir K; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA, Kote-Jarai Z.

Br J Cancer. 2016 Apr 12;114(8):945-52.


Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D, Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S, Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M, Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, Mcdonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Wokołorczyk D, Kluzniak W, Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T, Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Govindasami K, Guy M, Lophatonanon A, Muir K, Viñuela A, Brown AA; PRACTICAL Consortium; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; Australian Prostate Cancer BioResource; UK Genetic Prostate Cancer Study Collaborators; UK ProtecT Study Collaborators, Freedman M, Conti DV, Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z.

Hum Mol Genet. 2015 Oct 1;24(19):5589-602. doi: 10.1093/hmg/ddv203. Epub 2015 May 29.


Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.


Multiple loci on 8q24 associated with prostate cancer susceptibility.

Al Olama AA, Kote-Jarai Z, Giles GG, Guy M, Morrison J, Severi G, Leongamornlert DA, Tymrakiewicz M, Jhavar S, Saunders E, Hopper JL, Southey MC, Muir KR, English DR, Dearnaley DP, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Sawyer E, Lophatananon A; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper C, Donovan JL, Hamdy FC, Neal DE, Eeles RA, Easton DF.

Nat Genet. 2009 Oct;41(10):1058-60. doi: 10.1038/ng.452. Epub 2009 Sep 20.


Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial.

Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O'Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; MS01 Trial Management Group.

Lancet. 2008 May 17;371(9625):1685-94. doi: 10.1016/S0140-6736(08)60727-8.


Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.

Duley JA, Nethersell AB.

Adv Exp Med Biol. 1998;431:147-50. No abstract available.


Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.

Falcone A, Danesi R, Dargenio F, Pfanner E, Brunetti I, Del Tacca M, Nethersell AB, Conte PF.

J Clin Oncol. 1996 Mar;14(3):729-36.


A phase II study of oral piritrexim in recurrent high-grade (III, IV) glioma.

Bleehen NM, Newman HV, Rampling RP, Ramsay JR, Roberts JT, Bedford P, Nethersell AB.

Br J Cancer. 1995 Sep;72(3):766-8.


In vitro and in vivo studies on the action of BW502U83, an arylmethylaminopropanediol.

van der Graaf WT, Zijlstra JG, de Vries EG, Nethersell AB, Mulder NH.

Anticancer Drugs. 1995 Feb;6(1):34-9.


VAPEC-B chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma: a retrospective analysis of 45 patients.

Singer JM, Mijovic A, Pettingale KW, Nethersell A, Dobbs HJ, Samaratunga IR, Lakhani A, Mufti GJ.

Clin Oncol (R Coll Radiol). 1995;7(6):366-70.


The effect of BW12C on the radiosensitivity and necrosis of murine tissues and tumours.

Stevens G, Hill SA, Joiner MC, Joiner B, Johns H, Williams K, Denekamp J, Nethersell AB.

Australas Radiol. 1994 Aug;38(3):199-203.


Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.

Salisbury JR, Rapson NT, Codd JD, Rogers MV, Nethersell AB.

J Clin Pathol. 1994 Apr;47(4):313-7.


A phase II evaluation of human lymphoblastoid interferon (Wellferon) in relapsed high grade malignant glioma. Medical Research Council Brain Tumour Working Party.

Priestman TJ, Bleehen NM, Rampling R, Stenning S, Nethersell AJ, Scott J.

Clin Oncol (R Coll Radiol). 1993;5(3):165-8.


Phase I study of BW12C in combination with mitomycin C in patients with advanced gastrointestinal cancer.

Ramsay JR, Bleehen NM, Dennis I, Workman P, Ward R, Falk SJ, Bedford P, Wootton R, Nethersell AB.

Int J Radiat Oncol Biol Phys. 1992;22(4):721-5.


Monitoring metabolic responses after induction of hypoxia in the KHT tumour using 31P NMR spectroscopy.

Bremner JC, Counsell CJ, Edwards HS, Stratford IJ, Adams GE, Nethersell AB, Bedford P.

Int J Radiat Biol. 1991 Jul-Aug;60(1-2):363-7. No abstract available.


Protection of pig epidermis against radiation-induced damage by the infusion of BW12C.

van den Aardweg GJ, Hopewell JW, Adams GE, Barnes DW, Sansom JM, Stratford IJ, Nethersell AB.

Int J Radiat Biol. 1991 Apr;59(4):1039-51.


Biological modifiers and their role in cancer therapy.

Nethersell AB.

Ann Acad Med Singapore. 1990 Mar;19(2):223-34. Review.


Antibodies to lymphoblastoid interferon.

Galton JE, Bedford P, Scott JE, Brand CM, Nethersell AB.

Lancet. 1989 Sep 2;2(8662):572-3. No abstract available.


Supplemental Content

Loading ...
Support Center